The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

The biotechnology sector is in focus following reports that AbbVie (ABBV) is nearing an acquisition of Apogee Therapeutics ...

This biotech player is heading for a critical moment.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Biotech stocks combine scientific innovation with substantial R&D investment in cutting edge medicine. Biotech sector includes companies focused on gene editing and breakthroughs in rare disease ...